(-)-epigallocatechin gallate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: (-)-epigallocatechin gallate
• 英文别名: EGCG；[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,5-dihydroxy-4-methylbenzoate
• 化学式: C₂₃H₂₀O₁₀
• 分子量: 456.406
• InChiKey: BODLEJRYMFFAKU-IFMALSPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  177
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (-)-表没食子儿茶素 在 吡啶 、 咪唑 、 正丁基锂 、 potassium carbonate 、 triethylamine tris(hydrogen fluoride) 、 三羟甲基氨基甲烷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (-)-epigallocatechin gallate
  参考文献：
  名称：

  构效关系对多酚抑制人5α-还原酶的影响

  摘要：

  摘要类固醇5α-还原酶（EC 1.3.99.5）催化NADPH依赖性的多种3-oxo-Δ4类固醇双键双键还原，包括将睾丸激素转化为5α-二氢睾丸激素。在人类中，5α-还原酶活性对于男性性别分化的某些方面至关重要，并且可能参与良性前列腺增生，脱发，多毛症和前列腺癌的发展。某些天然产物包含的成分是5α-还原酶的抑制剂，例如绿茶儿茶素（-）-表没食子儿茶素没食子酸酯（EGCG）。EGCG在无细胞状态下显示出有效的抑制作用，但在5α-还原酶的全细胞分析中却没有。用长链脂肪酸代替EGCG中的没食子酸酯可产生有效的5α-还原酶抑制剂，该抑制剂在无细胞和全细胞分析系统中均具有活性。作为15α-还原酶有效抑制剂的其他类黄酮包括杨梅素，槲皮素，黄ical素和非瑟定。与1型同工酶相比，Biochanin A，黄豆苷元，染料木黄酮和山emp酚是2型抑制剂更好的抑制剂。几种其他天然和合成的多酚化合物比1型同功酶更

  DOI：

  10.1016/s0006-2952(02)00848-1

文献信息

• GLUCOSYLTRANSFERASE INHIBITOR CONTAINING EPIGALLOCATECHIN GALLATE POLYMER AS ACTIVE INGREDIENT
  申请人：Fukui Yuko

  公开号：US20110150790A1

  公开（公告）日：2011-06-23

  Provided is a highly palatable and safe glucosyltransferase inhibitor or anti-dental caries agent. A glucosyltransferase inhibitor or anti-dental caries agent having an epigallocatechin gallate polymer or a salt thereof. Particularly, the above agent containing an epigallocatechin gallate polymer, which is a compound in which chroman rings are bonded at position 6 and/or 8 via a methylene group.
• METHODS OF TREATING HEMATOLOGIC CANCERS
  申请人：Kay Neil E.

  公开号：US20120190638A1

  公开（公告）日：2012-07-26

  This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.
• US20140274937A1
  申请人：——

  公开号：US20140274937A1

  公开（公告）日：2014-09-18
• CDK5 Inhibitors and Therapeutic Uses Thereof
  申请人：The Hong Kong University of Science and Technology

  公开号：US20150119348A1

  公开（公告）日：2015-04-30

  Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.
• METHOD TO IDENTIFY COMPOUNDS ABLE TO BIND TO THE ROSSMANN FOLD OF C-TERMINAL-BINDING PROTEINS, IDENTIFIED COMPOUNDS AND MEDICAL USES THEREOF
  申请人：CONSIGLIO NAZIONALE DELLE RICERCHE

  公开号：US20170003275A1

  公开（公告）日：2017-01-05

  The invention refers to a method for identifying an anti-tumoral and/or anti-proliferative and/or an inhibitor of the fission machinery involved in mitotic Golgi partitioning and/or a molecule modulator of CtBP corepressor activity by testing their affinity binding for the Rossmann fold of C-terminal-binding proteins (CtBPs); to said identified molecules and to the use thereof as anti-proliferative and/or anti tumoral agents.